Figure 5.
Figure 5. Survival in AL. (A) Overall survival of 705 patients with AL followed at the Pavia Amyloid Center. (B) Survival according to heart involvement. (C) Survival according to response to chemotherapy in 454 patients. (D) Survival according to response to chemotherapy in 257 patients with heart involvement. There was no significant difference in either echocardiographic features or in the serum concentration of the cardiac biomarker NT-proBNP in nonresponders (median, 3952 ng/L; range, 96-56 764 ng/L) and responders (median, 3490 ng/L; range, 386-76 927 ng/L), respectively.

Survival in AL. (A) Overall survival of 705 patients with AL followed at the Pavia Amyloid Center. (B) Survival according to heart involvement. (C) Survival according to response to chemotherapy in 454 patients. (D) Survival according to response to chemotherapy in 257 patients with heart involvement. There was no significant difference in either echocardiographic features or in the serum concentration of the cardiac biomarker NT-proBNP in nonresponders (median, 3952 ng/L; range, 96-56 764 ng/L) and responders (median, 3490 ng/L; range, 386-76 927 ng/L), respectively.

Close Modal

or Create an Account

Close Modal
Close Modal